Analystreport

Trillium Therapeutics Inc. (NASDAQ: TRIL) is now covered by analysts at Benchmark Co.. They set a "buy" rating and a $21.00 price target on the stock.

Trillium Therapeutics Inc. - Common Shares  (TRIL) 
Last trillium therapeutics inc. - common shares earnings: 5/13 07:00 am Check Earnings Report